Collectively, these results imply the existence of ELAVL2-SH3GL3/DNM3 signaling axis in preventing the aggressive MES characteristics of GBM and, thus, modulation of these molecules may be a novel and effective therapeutic strategy for GBM patients. This evidence concerns the gene SH3GL3 and glioblastoma.